+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacotherapy in complicated parapneumonic pleural effusions and thoracic empyema



Pharmacotherapy in complicated parapneumonic pleural effusions and thoracic empyema



Pulmonary Pharmacology and Therapeutics 18(6): 381-389



Parapneumonic pleural effusions (PPE) and pleural empyema (PE) present a frequently diagnostic and therapeutic challenge in clinical practice. Although pleural diseases have received increased attention during the past decade, there are still many unanswered questions concerning the diagnosis and treatment of PPE and PE. A lack of controlled studies concerning the management of PPE and PE was noted in recent guidelines. The use of fibrinolytics intrapleurally appears to enhance intercostals tube drainage, reducing the requirement for subsequent surgical mechanical debridement. Recently, there has been interest in other intrapleural agents including combination drugs consisting of streptokinase and streptodornase-alpha, Dnase. Factors to be considered in evaluating whether or not intrapleural instillation of fibrinolytics is effective include an assessment of clinical responses. This review discusses the use of fibrinolytic agents as a novel therapeutic options for treating the various stages of parapneumonic effusions and empyemas.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012409860

Download citation: RISBibTeXText

PMID: 15998594

DOI: 10.1016/j.pupt.2004.12.001


Related references

Role of pleural fluid C-reactive protein concentration in discriminating uncomplicated parapneumonic pleural effusions from complicated parapneumonic effusion and empyema. Lung 184(3): 141-145, 2006

Treatment of empyema and complicated parapneumonic effusions with pleural fibrinolytics. Medicina Clinica 121(20): 795; Author Reply 176, 2003

Management of complicated parapneumonic effusions and thoracic empyema. Internal Medicine Journal 32(8): 408-414, 2002

Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema. European Respiratory Journal 9(8): 1656-1659, 1996

Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema. Journal of Bronchology and Interventional Pulmonology 24(1): 40-47, 2017

Treatment of complicated parapneumonic effusions and pleural empyema: a four-year prospective study. Singapore Medical Journal 37(6): 631-635, 1996

Role of interventional pulmonology in the management of complicated parapneumonic pleural effusions and empyema. Respirology 19(7): 970-978, 2014

Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 111(2): 275-279, 1997

A Simple Method for Differentiating Complicated Parapneumonic Effusion/Empyema from Parapneumonic Effusion Using the Split Pleura Sign and the Amount of Pleural Effusion on Thoracic CT. Plos one 10(6): E0130141, 2015

CT versus thoracic ultrasound for discriminating uncomplicated and complicated parapneumonic pleural effusions. Respirology 23(2): 232, 2018

Complicated parapneumonic effusion and empyema: pleural decortication and video-assisted thoracic surgery. Current Infectious Disease Reports 10(3): 236-240, 2008

Treatment of complicated parapneumonic pleural effusion and pleural parapneumonic empyema. Medical Science Monitor 18(7): Cr443, 2012

Precision-guided, Personalized Intrapleural Fibrinolytic Therapy for Empyema and Complicated Parapneumonic Pleural Effusions: The Case for the Fibrinolytic Potential. Clinical Pulmonary Medicine 24(4): 163-169, 2017

Management of parapneumonic pleural effusions and empyema. Infectious Disease Clinics of North America 5(3): 539-559, 1991

Development and Validation of the COMPLES Score for Differentiating Between Tuberculous Effusions with Low Pleural pH or Glucose and Complicated Parapneumonic Effusions. Lung 194(5): 847-854, 2016